One in Five People with MS Uses Cannabis for Symptom Relief

In a survey of 3,249 people with multiple sclerosis, 20% were currently using cannabis to treat symptoms, most commonly spasticity, pain, and sleep problems.

Salter, Amber et al.·International journal of MS care·2021·Moderate EvidenceCross-Sectional
RTHC-03488Cross SectionalModerate Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Cross-Sectional
Evidence
Moderate Evidence
Sample
N=3,249

What This Study Found

Among 3,249 respondents from the NARCOMS Registry, 31% had ever used cannabis for MS symptoms and 20% were current users, while 69% who had never tried it cited insufficient efficacy data (40%), safety concerns (27%), and legality (25%) as barriers.

Key Numbers

6,934 invited; 3,249 responded; 31% ever used cannabis for MS; 20% current users; spasticity (80%), pain (69%), sleep (61%) most common targets; barriers: insufficient efficacy data (40%), safety concerns (27%), legality (25%), cost (18%).

How They Did This

Cross-sectional supplemental survey of participants aged 18+ from the NARCOMS Registry (March-April 2020), reported with descriptive statistics.

Why This Research Matters

Despite limited clinical evidence, a substantial portion of MS patients are turning to cannabis for symptom management, suggesting a gap between patient needs and available evidence-based treatments.

The Bigger Picture

The high rate of cannabis use among MS patients, combined with common barriers like legal concerns and lack of efficacy data, suggests that clinical research on cannabis for MS symptoms has not kept pace with patient demand.

What This Study Doesn't Tell Us

Self-selected respondents from a patient registry; potential selection bias toward those with stronger opinions about cannabis; self-reported use without verification.

Questions This Raises

  • ?Do MS patients who use cannabis experience measurable improvements in spasticity and pain compared to those who don't?
  • ?Would access to more efficacy data change the usage rates among those who cited it as a barrier?

Trust & Context

Key Stat:
20% of MS patients surveyed currently use cannabis for symptom management
Evidence Grade:
Large survey from established patient registry provides moderate-quality descriptive data, limited by self-selection and self-report.
Study Age:
Survey conducted March-April 2020.
Original Title:
A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis.
Published In:
International journal of MS care, 23(6), 245-252 (2021)
Database ID:
RTHC-03488

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

A snapshot of a population at one point in time.

What do these levels mean? →

Frequently Asked Questions

What MS symptoms are people trying to treat with cannabis?

The most common symptoms targeted were spasticity (80%), pain (69%), and sleep problems (61%).

Why do some MS patients avoid using cannabis?

Among those who had never used cannabis for MS, 40% cited insufficient efficacy data, 27% had safety concerns, 25% were concerned about legality, and 18% cited cost.

Read More on RethinkTHC

Cite This Study

RTHC-03488·https://rethinkthc.com/research/RTHC-03488

APA

Salter, Amber; Fox, Robert J; Cutter, Gary; Marrie, Ruth Ann; Nichol, Kate E; Steinerman, Joshua R; Smith, Karry M J. (2021). A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis.. International journal of MS care, 23(6), 245-252. https://doi.org/10.7224/1537-2073.2021-036

MLA

Salter, Amber, et al. "A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis.." International journal of MS care, 2021. https://doi.org/10.7224/1537-2073.2021-036

RethinkTHC

RethinkTHC Research Database. "A Survey of Cannabis Use in a Large US-Based Cohort of Peopl..." RTHC-03488. Retrieved from https://rethinkthc.com/research/salter-2021-a-survey-of-cannabis

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.